Tumor repolarization by an advanced liposomal drug delivery system provides a potent new approach for chemo-immunotherapy
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Dokumenter
- Tumor repolarization by an advanced liposomal drug delivery system provides a potent new approach for chemo-immunotherapy
Forlagets udgivne version, 2,16 MB, PDF-dokument
Immunosuppressive cells in the tumor microenvironment allow cancer cells to escape immune recognition and support cancer progression and dissemination. To improve therapeutic efficacy, we designed a liposomal oxaliplatin formulation (PCL8-U75) that elicits cytotoxic effects toward both cancer and immunosuppressive cells via protease-mediated, intratumoral liposome activation. The PCL8-U75 liposomes displayed superior therapeutic efficacy across all syngeneic cancer models in comparison to free-drug and liposomal controls. The PCL8-U75 depleted myeloid-derived suppressor cells and tumor-associated macrophages in the tumor microenvironment. The combination of improved cancer cell cytotoxicity and depletion of immunosuppressive populations of immune cells is attractive for combination with immune-activating therapy. Combining the PCL8-U75 liposomes with a TLR7 agonist induced immunological rejection of established tumors. This combination therapy increased intratumoral numbers of cancer antigen-specific cytotoxic T cells and Foxp3-T helper cells. These results are encouraging toward advancing liposomal drug delivery systems with anticancer and immune-modulating properties into clinical cancer therapy.
Originalsprog | Engelsk |
---|---|
Artikelnummer | eaba5628 |
Tidsskrift | Science Advances |
Vol/bind | 6 |
Udgave nummer | 36 |
ISSN | 2375-2548 |
DOI | |
Status | Udgivet - 2020 |
Bibliografisk note
Publisher Copyright:
© 2020 The Authors, some rights reserved.
ID: 269499759